Annovis Bio Inc.
(ANVS)
undefined
undefined%
At close: undefined
5.31
0.95%
After-hours Dec 13, 2024, 07:00 PM EST
Company Description
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration.
The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders.
It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia.
The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.
Annovis Bio Inc.
| Country | United States |
| IPO Date | Jan 29, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Dr. Maria L. Maccecchini Ph.D. |
Contact Details
Address: 1055 Westlakes Drive Berwyn, Pennsylvania United States | |
| Website | https://www.annovisbio.com |
Stock Details
| Ticker Symbol | ANVS |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001477845 |
| CUSIP Number | 03615A108 |
| ISIN Number | US03615A1088 |
| Employer ID | 26-2540421 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Maria L. Maccecchini Ph.D. | Founder, Chief Executive Officer, President, Interim Principal Financial Officer & Executive Director |
| Blake Jensen | Head of Quality |
| Dr. Cheng Fang Ph.D. | Senior Vice President of Research & Development |
| Eve M. Damiano M.S., RAC | Senior Vice President of Regulatory Operations |
| Hilda Maibach | Senior Vice President of Statistics |
| Mark K. White | Chief Business Officer & Director |
| Melissa Gaines | Senior Vice President of Clinical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 11, 2024 | 8-K | Current Report |
| Dec 11, 2024 | 8-K | Current Report |
| Dec 11, 2024 | 424B5 | Filing |
| Dec 09, 2024 | 8-K | Current Report |
| Nov 12, 2024 | 8-K | Current Report |
| Nov 08, 2024 | 10-Q | Quarterly Report |
| Oct 15, 2024 | 8-K | Current Report |
| Sep 30, 2024 | 8-K | Current Report |
| Aug 15, 2024 | 8-K | Current Report |
| Aug 14, 2024 | 10-Q | Quarterly Report |